Clinical Trial Update: Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing efficacy of capecitabine as adjuvant therapy in high-risk HR+/HER2- breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Breast Cancer, Chemotherapy Effect | Phase 3 | Status: RECRUITING